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Carcinogen Risk Assessment
by Roy E. Albert*
A molecular biological rationale for the linear nonthreshold dose-response pattern for carcinogenesis is
presented based on the mutagenic activation ofoncogens as the basis ofinitiation. The approach assumes
that the linear nonthreshold dose pattern at very low doses applies only to tissues that are promoted by in-
trinsic and extrinsic agents other than the one being modeled, and that risk is charactertized on a relative
rather than absolute basis in terms ofaggregate tumor response.
Since this symposium is in honor of Norton Nelson I
want to say a few words about him. I have known Nor-
ton Nelson forliterally my entire professional life, going
back 40 years when I was a cardiovascular fellow in the
Department of Medicine with his war-time research
buddy, the great Ludwig Eichna. Nelson recruited me in
1959 to the Institute, and I worked there over 20 years
under hisleadership. Toput it in aword, he was a direc-
tor ofgenius. The combination ofareallypowerful mind
with anupbeat, forcefulpersonality gave the Institute an
intellectual glow that was ajoy. It was greatly reassur-
ing during all those years to knowthatthe Institute was
in the hands ofsomeone who was, by far, the best in his
field. His intellectual keenness, fund ofknowledge, and
grasp ofan extraordinarily wide range ofscience was al-
ways a source ofastonishment tome, and he was amodel
to emulate. As an administrator he was equallyphenom-
enalwith hisability tomake decisions aboutcomplexmat-
ters almostinstantly. I have never seen abettermanager
in terms oforganizaingcomplicated processeslikethefor-
mulation ofa NIEHS Centerproposal. When you put all
ofthis together in a person with a real depth ofculture
and agreattalkeryou have the one andonly Norton Nel-
son, the founder and guiding genius of the field of En-
vironmental Health. It is not surprising that since his
retirement as Director of the Institute he has been as
busy as ever being an advisor to everyone on a galactic
scale.
I would like to present some new ideas about carcino-
genriskassessment. One ofthethingsthat I valued most
in the years that I spent at this Institute under Norton
Nelson was the freedom to pursue one's interest. In my
case, it involved, amongst otherthings, the chairing the
Carcinogen Assessment Group at the U.S. Environmen-
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tal Protection Agency. Thisgroup developedvirtually all
ofthe methodology that is currently used in risk assess-
ment at the federal and state level. The quantitative
aspect ofrisk assessment involving dose-response rela-
tionships was taken overfromthefield ofionizingradia-
tion. In the Atomic Energy Commission the risks, for ex-
ample, ofcancer ofthe thyroid andbone fromradioactive
fallout were estimated usingalinearnonthreshold dose-
response model. The rationale for this was that cancer
must involve an irreversible genetic change and that mu-
tation was alikely candidate. The dose-response relation-
ship for radiation-induced mutations is linear, as is the
casegenerallywithchemical carcinogens. Thelinearnon-
threshold dose-response model quickly became the dom-
inant concept in quantitative risk assessment. This was
because any dose, however small, had a calculable risk.
The linearnonthreshold model has been, and still is, the
only extrapolation model that is used generally.
Ironically, the Federal regulatory agencies have dis-
avowed the mutational mechanistic basis for the linear
nonthreshold dose-response model while continuing to
use it. It is well recognized that the characterization of
low-level dose-response patterns cannotbe done by direct
observation either in animal bioassays or in human
epidemiologic studies. The confidence in the nature ofthe
low-dose extrapolation model comes from its conformity
to an understanding ofcarcinogenic mechanisms. To dis-
avow the mechanistic basis for the single-hit linear ki-
netics and yet continue to use the model for risk estima-
tion is not a very strong position.
The idea that the linear nonthreshold dose-response
model might represent the initiation component of the
two-stage initiation-promotion model occurred to my col-
league Fred Burns and me several years ago, on the ba-
sis ofexperimental datathat we developed dealingwith
dose-response in the two-stage mouse skin model. The
dose response forgraded doses ofbenzo(a)pyrene with a
standard promotional pattern using the promoter phor-R. E. ALBERT
bol myristate acetate (PMA) was highly consistent with
a linear nonthreshold dose-response pattern over three
to four orders of magnitude of initiating dose (1). The
same thing was true for the formation of BaP-DNA ad-
ducts in the mouse epidermis withgraded single doses of
BaP(2). Weproposed the idea afewyears ago(3)thatthe
linear nonthreshold extrapolation might applyto only the
initiation process ratherthanto complete carcinogenesis.
The enthusiasm that greeted the notion was subliminal.
However, the concept has revived with considerable
force due to developments inmolecular oncology. Ofthe
various modes ofactivation ofprotooncogenes, namely,
by insertion, amplification, translocation, and mutation,
the mutational mode is the one that is highly consistent
with a linear nonthreshold dose-response model. More-
over, the exciting finding was that the activation ofras
oncogene bymutationgenerally ofcodon 61 or 12isfound
in the early stage ofthe initiationpromotionmodel inthe
mouse skin (4). In other words, the activated ras on-
cogene isfoundinpapillomas brought outin skinby PMA
initiated with apolycyclic aromatic hydrocarbon, and the
activation ofthe ras oncogenepersists frompapillomato
carcinoma.
This sequence ofbenign tumorsthat eventullybecome
malignant is characteristic ofaninitiation-promotion sys-
tem, and it is seen in human colon cancer. Here, polyps
develop that eventually progress to carcinomas. It has
been observed that in lesions where the original polyp
and the carcinoma are seen together, the activated ras
gene is present in both, which is the same circumstance
as seen inthe mouse initiation-promotion skinmodel (5).
All ofthis suggests that a single hit process, namely, ac-
tivation ofthe ras protooncogene by mutation, could be
the initiating lesion in the carcinogenic process.
This puts a rather novel twist to a view of the dose-
response. Itimplies that at high doses there willbe com-
plete carcinogenesis. But, as the dose is diminished, the
effect of the carcinogen is largely that of initiation be-
cause thepromotingactionfadesaway; whether tumors
become manifest then depends onthe amount ofpromo-
tion present in the tissue from other sources. The impli-
cations arethat there are two kindsofdose-response pat-
terns: one in promoted tissues, where low doses will
produce the sequence ofbenign tomalignanttumors; and
the other in nonpromoted tissues, where, as the dose of
the agent isreduced, the formation oftumors simply dis-
appears.
It seemsreasonable thatgenotoxic agents that are car-
cinogenic at high doses are probably initiators at low
doses. It is also possible that genotoxic noncarcinogens
are also initiators at low doses and equally hazardous.
This logic does not apply to nongenotoxic agents that are
carcinogenic at high doses; it implies that the nongeno-
toxic carcinogens do not follow a linear nonthreshold
model. Carcinogenic responses with genotoxic carcino-
gens at high doses does not mean that there will neces-
sarily be any tumor response at low doses since this de-
pends on the presence of promotion. It is, therefore,
conceivable thatthepattern oftumorresponses wouldbe
different athigh andlow doses. As ahypothetical exam-
ple, liver and kidney tumors might form at high doses,
whereas atlow dosesmammary tumors might dominate
because ofhormonal promotion; at low doses the occur-
rence ofliver and kidneytumors couldbe absentbecause
initiated cells in those organs are not promoted. One
might expect that mammary tumors would occurat high
doses as well as at low doses, butthe occurrence at high
doses could be partially concealed by a censoring effect
of earlier tumor development in the liver and kidney.
The question arises as to how one recognizes promoted
tissue. As a first approximation it may be those tissues
thatundergo episodicgrowth andinvolutionbyhormonal
action or have an abnormally high cell proliferation rate
due to disease processes such asgastriculcers, colitis, os-
teomyelitis, orby the action ofexternal agents that are
toxic, such as alcohol onthe uppergastrointestinal tract,
cigarette smoke on therespiratory tract, infection ofthe
cervix, orviral hepatitis, etc. Perhaps itis time to revive
the old Virchow Chronic Irritation theory ofcancer in a
new form. Virchow's theory, which held sway for about
50 years until the 1930s, argued that chronic irritation
with elevated cell turnover was the nonspecific and
general cause ofcancer. It might now be appropriate to
thinkofVirchow's theory as atheory ofpromotionwhere
thefinal commonpathwayforpromotingagentsisheight-
ened cell proliferation. The initiation-promotion view of
carcinogenesis would include initiation by carcinogens
and spontaneous initiation (presumably as in the case of
spontaneous animal tumors) andpromotionby extrinsic
chemicals, overnutrition, hormonal promotion, promotion
by chronicviralinfections, and chronicinflammatorypro-
cesses as in autoimmune disease and possibly hyper-
proliferative states associated with tissue atrophy.
Drawingbackfrom this cosmic view ofcancerto the is-
sue at hand, namely risk assessment, the position being
advanced here is that low-dose risks from genotoxic
agents are limited to promoted tissues. It is difficult to
know exactly which tissues are going to be initiated by
a given carcinogen, but this depends somewhat on the
route of exposure. For example, it is clear that inhaled
carcinogens such as bis-chloromethylether or formalde-
hyde react completely in the respiratory tract, whereas
an inhaled agentlike 1,3-butadiene thatproduces tumors
in a wide variety of organs in mice would have to be
regarded as a more diffuse carcinogen.
A simplified generalization would be to regard all tis-
sues that show abackground tumor occurrence asbeing
promoted onthe supposition thattheymustbepromoted
inorderto develop tumors. Thedirect-actingagentswith
a high degree ofreactivity would be localized to the or-
gans ofinitial contact, while the otherswouldbe assumed
to affect all tissues. It could be assumed that the ag-
gregate tumor response induced in the animal would be
translated to humans. Thus, the dose of 1,3-butadiene
that causes a doubling ofall tumors in the mouse would
be assumed to double all tumors inhumans. Agentsthat
reactonly atinitial sites ofcontact, such asformaldehyde,
wouldbe expected to have effects onbackground tumors
only in that organ system in both animals and humans.
Forexample, aformaldehyde exposure that doubles the
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background occurrence ofspontaneous tumors in the rat
nose would be expected to do the same in the human
nose; in addition it would be expected to increase the
background tumoryield in humans lower in the respira-
tory tract: the nasopharynx, larynx, andtracheobronchial
tree inrelation to the amount ofdose that reaches these
parts. Extrapolation to doses below the doubling dose
would be done on a linear nonthreshold basis because of
the experimental evidence developed. Whatisproposed
here is arelative riskapproach, comparedtothe absolute
riskmethodcurrentlybeingused. Theproposed approach
also tends to break away from the painting-by-the-
numbers mentality that is characteristic of current
carcinogen-assessment thinking. It opens up the biolog-
ical question ofwhatisthe basisforlow-level carcinogen-
esis and whether the initiation-promotion model ad-
vancedhereisvalid; ifso, how cantheprocessbebrought
into sharper focus, e.g., to what extent do adducts ofdif-
ferent types initiate cells in different tissuesand how do
the different classes ofpromotors interact with the ini-
tiated cells induced by the different kinds of genotoxic
agents.
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